Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04691804
Title A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Jiangsu HengRui Medicine Co., Ltd.
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Fluzoparib + Prednisone

Abiraterone + Prednisone

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | BEL


No variant requirements are available.